tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

FOLD Stock Latest News

Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer
Company AnnouncementsAmicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer
24d ago
FOLD
Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer
PremiumCompany Announcements
Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer
26d ago
FOLD
Amicus’s Strong Performance and Growth Potential Drive Buy Rating
PremiumRatings
Amicus’s Strong Performance and Growth Potential Drive Buy Rating
1M ago
FOLD
Amicus price target raised to $18 from $16 at JPMorgan
PremiumThe Fly
Amicus price target raised to $18 from $16 at JPMorgan
1M ago
FOLD
Amicus Therapeutics Reports Strong Growth Amid Strategic Advances
PremiumCompany Announcements
Amicus Therapeutics Reports Strong Growth Amid Strategic Advances
1M ago
FOLD
Strong Growth and Strategic Expansion Drive Buy Rating for Amicus Therapeutics
PremiumRatingsStrong Growth and Strategic Expansion Drive Buy Rating for Amicus Therapeutics
1M ago
FOLD
Amicus Therapeutics: Strong Financial Performance and Strategic Positioning Drive Buy Rating
Premium
Ratings
Amicus Therapeutics: Strong Financial Performance and Strategic Positioning Drive Buy Rating
1M ago
FOLD
Amicus Therapeutics Reports Strong Q2 2025 Growth
Premium
Company Announcements
Amicus Therapeutics Reports Strong Q2 2025 Growth
1M ago
FOLD
Amicus Therapeutics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
PremiumRatings
Amicus Therapeutics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
1M ago
FOLD
Amicus Therapeutics: Strong Q2 Performance Amid Competitive Uncertainties Warrants Hold Rating
PremiumRatings
Amicus Therapeutics: Strong Q2 Performance Amid Competitive Uncertainties Warrants Hold Rating
1M ago
FOLD
Amicus reports Q2 EPS 1c, consensus 2c
PremiumThe Fly
Amicus reports Q2 EPS 1c, consensus 2c
1M ago
FOLD
Amicus sees FY25 revenue growth 15%-22%
PremiumThe Fly
Amicus sees FY25 revenue growth 15%-22%
1M ago
FOLD
FOLD Earnings this Week: How Will it Perform?
PremiumPre-EarningsFOLD Earnings this Week: How Will it Perform?
1M ago
FOLD
Starbucks downgraded, Oracle initiated: Wall Street’s top analyst calls
Premium
The Fly
Starbucks downgraded, Oracle initiated: Wall Street’s top analyst calls
2M ago
V
MA
Amicus upgraded to Overweight from Equal Weight at Morgan Stanley
Premium
The Fly
Amicus upgraded to Overweight from Equal Weight at Morgan Stanley
2M ago
FOLD
Amicus upgraded to Overweight from Equal Weight at Morgan Stanley
PremiumThe Fly
Amicus upgraded to Overweight from Equal Weight at Morgan Stanley
2M ago
FOLD
Amicus Therapeutics Advances Pediatric Fabry Disease Study with Migalastat
PremiumCompany Announcements
Amicus Therapeutics Advances Pediatric Fabry Disease Study with Migalastat
2M ago
FOLD
Amicus Therapeutics Advances Pompe Disease Research with New Observational Study
PremiumCompany Announcements
Amicus Therapeutics Advances Pompe Disease Research with New Observational Study
2M ago
FOLD
Amicus Therapeutics’ Migalastat Study: A Potential Game-Changer for Fabry Disease Treatment
PremiumCompany Announcements
Amicus Therapeutics’ Migalastat Study: A Potential Game-Changer for Fabry Disease Treatment
2M ago
FOLD
Amicus Therapeutics Expands Access to Migalastat for Fabry Disease Patients
PremiumCompany AnnouncementsAmicus Therapeutics Expands Access to Migalastat for Fabry Disease Patients
2M ago
FOLD
Amicus Therapeutics Completes Key Study on Pompe Disease Treatment Interactions
Premium
Company Announcements
Amicus Therapeutics Completes Key Study on Pompe Disease Treatment Interactions
2M ago
FOLD
Amicus announces approval of Pombiliti + Opfolda in Japan
Premium
The Fly
Amicus announces approval of Pombiliti + Opfolda in Japan
2M ago
FOLD

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >